光化性角化病市場：依治療類型、最終用戶、地區

Actinic Keratosis Market, By Treatment Type, By End User, By Geography

出版日期: 2024年05月02日 | 出版商:

Coherent Market Insights | 英文 175 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計2024年全球光化性角化病市場規模為87.3億美元，預計2031年將達到122.3億美元，2024年至2031年的年複合成長率為4.9%。

報告範圍		報告詳情
基準年	2023年	2024年市場規模	87.3億美元
實際資料	2019年至2023年	預測期	從2024年到2031年
預測 2024-2031 年年複合成長率：	4.90%	2031年價值預測	122.3億美元

圖：2024 年光化性角化病市場佔有率（%），依地區分類

光化性角化症是一種因長期暴露於太陽紫外線而引起的癌前皮膚病。其特徵是暴露在陽光下的部位出現鱗片狀或硬皮斑塊，例如臉部、嘴唇、耳朵、禿頂、前臂、手背和下唇。這些斑點是由表皮上層角質形成細胞異常且不受控制的增殖引起的。如果不及時治療，它可能會發展成鱗狀細胞癌，這是一種皮膚癌。人們對皮膚健康和早期診斷的認知不斷提高，正在推動全球光化性角化病市場的成長。

市場動態：

全球光化性角化症市場主要是由曬傷導致的盛行率不斷上升所推動的。長期無保護的紫外線照射是光化性角化症的主要危險因子。隨著戶外休閒活動和職業陽光照射的增加，對有效治療和管理方案的需求正在穩步增加。此外，優惠的治療方法報銷政策和新治療方法的核准增加也推動了市場的成長。然而，品牌藥的高價格仍然是一個重大挑戰。繼續研究具有更好療效和更短治療時間的新製劑可能會克服這一挑戰，並為全球光化性角化病市場提供進一步的成長機會。

本研究的主要特點

本報告對全球光化性角化病市場進行了詳細分析，並列出了以2023年為基準年的預測期（2024-2031年）的市場規模和年複合成長率（CAGR%）。
它還強調了各個細分市場的潛在收益成長機會，並說明了該市場有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
根據公司亮點、產品系列、主要亮點、業績和策略等參數對全球光化性角化病市場的主要企業進行了介紹。
主要企業包括Almirall, SA、Bausch Health Companies Inc.、Perrigo Company plc.、Sun Pharmaceutical Industries Ltd.、Hill Dermaceuticals, Inc.、Tolmar Pharmaceuticals, Inc.、Bioforntera AG、Cipher Pharmaceuticals Inc.、Vidac、Athenex, Inc. 。
該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
全球光化性角化病市場迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
透過用於分析全球光化性角化病市場的各種策略矩陣，將促進相關人員的決策。

Report Coverage	Report Details
Base Year:	2023	Market Size in 2024:	US$ 8.73 Bn
Historical Data for:	2019 To 2023	Forecast Period:	2024 To 2031
Forecast Period 2024 to 2031 CAGR:	4.90%	2031 Value Projection:	US$ 12.23 Bn

Actinic keratosis is a precancerous skin condition caused by prolonged exposure to UV radiation from the sun. It is characterized by scaly or crusty patches that develop on sun-exposed areas like the face, lips, ears, bald scalp, forearms, the back of the hands, and lower lips. These patches are caused by the abnormal and uncontrolled growth of keratinocytes in the upper layer of the epidermis. If left untreated, actinic keratosis has the potential to develop into squamous cell carcinoma, a type of skin cancer. Rising awareness regarding skin health and early diagnosis has been driving the global actinic keratosis market growth.

Market Dynamics:

The global actinic keratosis market is primarily driven by the increasing prevalence of the condition owing to sun exposure. Prolonged and unprotected exposure to ultraviolet radiation is the main risk factor for actinic keratosis. With rising outdoor recreational activities and occupational sun exposure, the demand for effective treatment and management options is steadily increasing. Additionally, favorable reimbursement policies for treatment procedures and increasing approval of new treatment modalities are providing impetus to the market growth. However, high cost of branded drugs remains a key challenge. Ongoing research into new formulations with better efficacy and reduced treatment duration can help overcome this challenge and further create growth opportunities in the global actinic keratosis market.

Key Features of the Study:

This report provides an in-depth analysis of the global actinic keratosis market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global actinic keratosis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this includes Almirall, S.A, Bausch Health Companies Inc., Perrigo Company plc., Sun Pharmaceutical Industries Ltd., Hill Dermaceuticals, Inc., Tolmar Pharmaceuticals, Inc., Bioforntera AG, Cipher Pharmaceuticals Inc., Vidac, Athenex, Inc., GALDERMA, and LEO Pharma A/S.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
Global actinic keratosis market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global actinic keratosis market.

Detailed Segmentation-

By Treatment Type:
- Topical Treatment
- Surgical Procedure
- Chemical peels
- Cryosurgery
- Curettage and desiccation
- Others
- Photodynamic Therapy
- Others
By End User:
- Hospitals
- Dermatology Clinics
- Spas and Rejuvenation Centers
- Homecare Settings
- Others
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Almirall, S.A
- Bausch Health Companies Inc.
- Perrigo Company plc.
- Sun Pharmaceutical Industries Ltd.
- Hill Dermaceuticals, Inc.
- Tolmar Pharmaceuticals, Inc.
- Bioforntera AG
- Cipher Pharmaceuticals Inc.
- Vidac
- Athenex, Inc.
- GALDERMA
- LEO Pharma A/S

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Treatment Type
- Market Snapshot, By End User
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Scenario
Acquisitions and Partnerships Scenario
Product Launches/Approvals
Brand and Pricing Analysis
Funding and Investments
PEST Analysis
Porter's Analysis

4. Global Actinic Keratosis Market - Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the Market

5. Global Actinic Keratosis Market, By Treatment Type, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Topical Treatment
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Surgical Procedure
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Chemical peels
Cryosurgery
Curettage and desiccation
Others
Photodynamic Therapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Actinic Keratosis Market, By End User, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Hospitals
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Dermatology Clinics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Spas and Rejuvenation Centers
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Homecare Settings
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Actinic Keratosis Market, By Region, 2019 - 2031, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2019-2031
- Regional Trends
  - North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - U.S.
  - Canada
  - Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
  - Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
  - Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
  - Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - GCC
  - Israel
  - Rest of Middle East
  - Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Company Profiles
- Almirall, S.A
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Bausch Health Companies Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Perrigo Company plc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Sun Pharmaceutical Industries Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Hill Dermaceuticals, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Tolmar Pharmaceuticals, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Bioforntera AG
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Cipher Pharmaceuticals Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Vidac
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Athenex, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- GALDERMA
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- LEO Pharma A/S
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies